Tivozanib is primarily used as a targeted therapy in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, specifically targeting vascular endothelial growth factor receptors (VEGFRs). By inhibiting these receptors, Tivozanib helps to block the formation of new blood vessels that supply tumors, thereby slowing down tumor growth and spread. Its application is particularly beneficial for patients who have not responded well to other treatments, offering a more focused approach to managing the disease. The drug is administered orally, making it convenient for patients to use as part of their ongoing cancer treatment regimen. Clinical studies have shown that Tivozanib can improve progression-free survival in patients with advanced RCC, making it a valuable option in the oncology field.